The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review)
- Authors:
- Sarah Hsin Cheng
- Kuan-Yi Tu
- Hsin-Hua Lee
-
Affiliations: Department of Clinical Education and Training, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., School of Post Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C. - Published online on: June 11, 2024 https://doi.org/10.3892/or.2024.8755
- Article Number: 96
-
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao Y and Zhuang H: Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front Immunol. 13:10258722022. View Article : Google Scholar : PubMed/NCBI | |
|
Billing DL and Rimner A: Results of radiation therapy as local ablative therapy for oligometastatic non-small cell lung cancer. Cancers (Basel). 13:57732021. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN and Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 170:6338–6347. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J and Hodge JW: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64:7985–7994. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG and Lord EM: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 174:7516–7523. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Schaue D, Ratikan JA, Iwamoto KS and McBride WH: Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 83:1306–1310. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Navarro-Martín A, Galiana IL, Berenguer Frances MA, Cacicedo J, Cañas Cortés R, Comas Anton S, Padrones Sánchez S, Bolívar Cuevas S, Parry R and Guedea Edo F: Preliminary study of the effect of stereotactic body radiotherapy (SBRT) on the immune system in lung cancer patients unfit for surgery: Immunophenotyping analysis. Int J Mol Sci. 19:39632018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou P, Chen D, Zhu B, Chen W, Xie Q, Wang Y, Tan Q, Yuan B, Zuo X, Huang C, et al: Stereotactic body radiotherapy is effective in modifying the tumor genome and tumor immune microenvironment in non-small cell lung cancer or lung metastatic carcinoma. Front Immunol. 11:5942122021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q, Zhang Z, Wang Z, Wu D, Wu P, et al: Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep. 7:48662017. View Article : Google Scholar : PubMed/NCBI | |
|
Lockney NA, Zhang M, Morris CG, Nichols RC, Okunieff P, Swarts S, Zhang Z, Zhang B, Zhang A and Hoppe BS: Radiation-induced tumor immunity in patients with non-small cell lung cancer. Thorac Cancer. 10:1605–1611. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lei QQ, Sui JD, Jin F, Luo HL, Shan JJ, Tang L, Wang Y and Wu YZ: Impact of high-dose rate radiotherapy on B and natural killer (NK) cell polarization in peripheral blood mononuclear cells (PBMCs) via inducing non-small cell lung cancer (NSCLC)-derived exosomes. Transl Cancer Res. 10:3538–3547. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Gao M, Huang Z, Yu J and Meng X: SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 13:1052020. View Article : Google Scholar : PubMed/NCBI | |
|
Breen WG, Leventakos K, Dong H and Merrell KW: Radiation and immunotherapy: Emerging mechanisms of synergy. J Thorac Dis. 12:7011–7023. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Heinzerling JH, Mileham KF and Simone CB II: The utilization of immunotherapy with radiation therapy in lung cancer: A narrative review. Transl Cancer Res. 10:2596–2608. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
He J and Hu Q: Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer. Front Immunol. 14:11265822023. View Article : Google Scholar : PubMed/NCBI | |
|
Luna J, Zafra J, Areses Manrique MC, Rodríguez A, Sotoca A, Fírvida JL, Chicas-Sett R, Mielgo X, Reyes JCT and Couñago F: New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World J Clin Oncol. 12:983–999. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schlick B, Shields MD, Marin-Acevedo JA, Patel I and Pellini B: Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer. Curr Treat Options Oncol. 23:1104–1120. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Azghadi S and Daly ME: Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treat Res Commun. 26:1002982021. View Article : Google Scholar : PubMed/NCBI | |
|
Chicas-Sett R, Zafra-Martin J, Morales-Orue I, Castilla-Martinez J, Berenguer-Frances MA, Gonzalez-Rodriguez E, Rodriguez-Abreu D and Couñago F: Immunoradiotherapy as an effective therapeutic strategy in lung cancer: From palliative care to curative intent. Cancers (Basel). 12:21782020. View Article : Google Scholar : PubMed/NCBI | |
|
Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, et al: Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin Cancer Res. 24:5368–5380. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, et al: Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med. 20:5412022. View Article : Google Scholar : PubMed/NCBI | |
|
Han MG, Wee CW, Kang MH, Kim MJ, Jeon SH and Kim IA: Combination of OX40 co-stimulation, radiotherapy, and PD-1 inhibition in a syngeneic murine triple-negative breast cancer model. Cancers (Basel). 14:26922022. View Article : Google Scholar : PubMed/NCBI | |
|
Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, et al: Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models. Front Immunol. 12:7638882021. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, et al: A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 51:2321–2329. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien MER, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J and Reck M; SR-ON-12 Study Group, : SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol. 15:906–914. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Wang XL, Deng QL, Du YQ and Zhao NQ: The efficacy and safety of immunotherapy in patients with advanced NSCLC: A systematic review and meta-analysis. Sci Rep. 6:320202016. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong W, Zhao Y, Du H and Guo X: Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol. 11:7043362021. View Article : Google Scholar : PubMed/NCBI | |
|
Schild SE, Wang X, Bestvina CM, Williams T, Masters G, Singh AK, Stinchcombe TE, Salama JK, Wolf S, Zemla T, et al: Alliance A082002-a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 23:e317–e320. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, et al: Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol. 15:59–68. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar SS, Higgins KA and McGarry RC: Emerging therapies for stage III non-small cell lung cancer: stereotactic body radiation therapy and immunotherapy. Front Oncol. 7:1972017. View Article : Google Scholar : PubMed/NCBI | |
|
Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D and Jabbour SK: Combining radiation therapy and immunotherapy for lung cancers: A narrative review. Shanghai Chest. 5:102021. View Article : Google Scholar : PubMed/NCBI | |
|
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18:895–903. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson M and Rosenzweig KE: The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res. 8:48–57. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Murray L, Karakaya E, Hinsley S, Naisbitt M, Lilley J, Snee M, Clarke K, Musunuru HB, Ramasamy S, Turner R and Franks K: Lung stereotactic ablative radiotherapy (SABR): Dosimetric considerations for chest wall toxicity. Br J Radiol. 89:201506282016. View Article : Google Scholar : PubMed/NCBI | |
|
Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R and Chang JY: Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 81:91–96. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Owen D and Sio TT: Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors. J Thorac Dis. 12:7024–7031. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, Jolly S, Meyers B, Rocco G, Rusthoven C, et al: Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American society of clinical oncology endorsement of the American society for radiation oncology evidence-based guideline. J Clin Oncol. 36:710–719. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 35:709–717. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, et al: Lung stereotactic body radiation therapy and concurrent immunotherapy: A multicenter safety and toxicity analysis. Int J Radiat Oncol Biol Phys. 108:304–313. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ and Juloori A: Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy. Int J Radiat Oncol Biol Phys. 114:645–654. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Simone CB II, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, et al: Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline. Pract Radiat Oncol. 10:158–173. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stahel RA, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J, Karrer K, Maurer LH, Osterlind K and van Houtte P: Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer. 5:119–126. 1989. View Article : Google Scholar | |
|
Jones GS, Elimian K, Baldwin DR, Hubbard RB and McKeever TM: A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer. 141:44–55. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Verma V, Simone CB II, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, et al: Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys. 97:362–371. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, et al: Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study. J Immunother Cancer. 8:e0013022020. View Article : Google Scholar : PubMed/NCBI | |
|
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, et al: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 36:1611–1618. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Theelen WSEM, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Patel RR, Verma V, Ramapriyan R, Barsoumian HB, Cortez MA and Welsh JW: Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 150:114–120. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YS, Li Z, Xiao ZF, Li D and Liu WY: Case report: Radiotherapy plus pneumococcal conjugate vaccine stimulates abscopal immune response in a patient with ALK+ NSCLC. Front Immunol. 13:9502522022. View Article : Google Scholar : PubMed/NCBI | |
|
de Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, et al: Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 10:e0043712022. View Article : Google Scholar | |
|
Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, et al: Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 7:382019. View Article : Google Scholar : PubMed/NCBI | |
|
Román-Jobacho A, Hernández-Miguel M, García-Anaya MJ, Gómez-Millán J, Medina-Carmona JA and Otero-Romero A: Oligometastatic non-small cell lung cancer: Current management. J Clin Transl Res. 7:311–319. 2021.PubMed/NCBI | |
|
Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA and Louie AV: A Review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead? Front Oncol. 9:5432019. View Article : Google Scholar : PubMed/NCBI | |
|
Milano MT, Biswas T, Simone CB II and Lo SS: Oligometastases: History of a hypothesis. Ann Palliat Med. 10:5923–5930. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bates JE and Milano MT: Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. J Thorac Dis. 9:1903–1910. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, Hochstenbag MM, Smit EF and Dingemans AM: Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. Eur J Cancer. 51:2534–2544. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et al: Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 37:1558–1565. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, et al: Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 4:e1735012018. View Article : Google Scholar : PubMed/NCBI | |
|
Brandão M, Durieux V and Berghmans T: Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review. Transl Lung Cancer Res. 10:3473–3485. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, et al: Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial. JAMA Oncol. 5:1283–1290. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe T, Firat E, Scholber J, Gaedicke S, Heinrich C, Luo R, Ehrat N, Multhoff G, Schmitt-Graeff A, Grosu AL, et al: Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother. 69:1823–1832. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Griswold CR, Kerrigan K and Patel SB: Combination of local ablative therapy and continuation of immune checkpoint inhibitor (ICI) therapy provides durable treatment response past oligometastatic progression in NSCLC: A case report. Case Rep Oncol. 12:866–871. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, et al: Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23:781–792. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, et al: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial. BMC Cancer. 20:5572020. View Article : Google Scholar : PubMed/NCBI | |
|
Van Limbergen EJ, Hoeben A, Lieverse RIY, Houben R, Overhof C, Postma A, Zindler J, Verhelst F, Dubois LJ, De Ruysscher D, et al: Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: A phase 1 study. Int J Radiat Oncol Biol Phys. 109:1421–1430. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Jiang S, Lin Y, Yu H, Yu L and Zhang X: Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis. Front Oncol. 12:10665572022. View Article : Google Scholar : PubMed/NCBI | |
|
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J and McGarry RC: Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study. Int J Radiat Oncol Biol Phys. 85:1325–1331. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Qiang Y, Shen Q, Zhu XX and Song Y: Neoadjuvant programmed cell death protein 1 blockade combined with stereotactic body radiation therapy for stage III(N2) non-small cell lung cancer: A case series. Front Oncol. 12:7792512022. View Article : Google Scholar : PubMed/NCBI | |
|
Luna J, Sotoca A, Fernández P, Miralles C and Rodríguez A: Recent advances in early stage lung cancer. J Clin Transl Res. 7:163–174. 2021.PubMed/NCBI | |
|
Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, et al: Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial. Lancet Oncol. 20:494–503. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Daly ME, Redman M, Simone CB, Monjazeb AM, Bauman JR, Hesketh P, Feliciano J, Kashani R, Steuer C, Ganti AK, et al: SWOG/NRG S1914: A randomized phase III trial of induction/consolidation atezolizumab + SBRT vs SBRT alone in high risk, early-stage NSCLC (NCT#04214262). Int J Radiat Oncol Biol Phys. 114:e4142022. View Article : Google Scholar | |
|
Hallqvist A, Koyi H, de Petris L, Lindberg K, Farooqi S, Helland Å, Wikström A, Johansson M, Planck M, Lindberg L, et al: 63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). J Thorac Oncol. 16 (Suppl):S729–S730. 2021. View Article : Google Scholar | |
|
Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, et al: Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. J Clin Oncol. 37:1316–1325. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, et al: 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 123:3031–3039. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Verma V and Simone CB II: Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer. Transl Lung Cancer Res. 8:70–77. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H and Katsuda Y: The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection. J Thorac Cardiovasc Surg. 108:684–686. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Strauss GM, Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 26:5043–5051. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
National Comprehensive Cancer Network, . Non-small cell lung cancer. (version 2.2024). 2024. | |
|
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Liu C, Xie G, Wu F and Hu C: Multiple primary lung cancers: A new challenge in the era of precision medicine. Cancer Manag Res. 12:10361–10374. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Boyle JM, Tandberg DJ, Chino JP, D'Amico TA, Ready NE and Kelsey CR: Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis. Cancer. 121:598–604. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al: Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Woody S, Hegde A, Arastu H, Peach MS, Sharma N, Walker P and Ju AW: Survival is worse in patients completing immunotherapy prior to SBRT/SRS compared to those receiving it concurrently or after. Front Oncol. 12:7853502022. View Article : Google Scholar : PubMed/NCBI | |
|
Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, et al: A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J Thorac Oncol. 17:130–140. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, et al: Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: Outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol Res. 7:1903–1909. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Windisch P and Guckenberger M: Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: Another step forward on the long road of evidence-based medicine for oligometastatic disease. J Thorac Dis. 11 (Suppl 15):S1869–S1873. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, et al: Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 26:1134–1142. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, et al: P Phase II study of immunotherapy with tecemotide and bevacizumab after chemoradiation in patients with unresectable stage III non-squamous non-small-cell lung cancer (NS-NSCLC): A trial of the ECOG-ACRIN cancer research group (E6508). Clin Lung Cancer. 21:520–526. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alite F, Shaikh PM and Mahadevan A: Influence of dexamethasone premedication on acute lung toxicity in lung SBRT. Front Oncol. 12:8375772022. View Article : Google Scholar : PubMed/NCBI | |
|
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al: Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 36:2872–2878. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al: Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 537:417–421. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, et al: A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 18:e349–e360. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nikitas J, Roach M, Robinson C, Bradley J, Huang J, Perkins S, Tsien C and Abraham C: Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 21:32–35. 2019.PubMed/NCBI | |
|
Rodríguez Plá M, Dualde Beltrán D and Ferrer Albiach E: Immune checkpoints inhibitors and SRS/SBRT synergy in metastatic non-small-cell lung cancer and melanoma: A systematic review. Int J Mol Sci. 22:116212021. View Article : Google Scholar : PubMed/NCBI | |
|
Shields MD, Chen K, Dutcher G, Patel I and Pellini B: Making the rounds: Exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 23:90062022. View Article : Google Scholar : PubMed/NCBI | |
|
Spaas M, Sundahl N, Hulstaert E, Kruse V, Rottey S, De Maeseneer D, Surmont V, Meireson A, Brochez L, Reynders D, et al: Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): Study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer. 21:5142021. View Article : Google Scholar : PubMed/NCBI | |
|
Ni J, Yang L, Zhu H, Chu M, Zhang C, Zhao W, Yang M, Xu X, Zheng E, Jiang X, et al: A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: A case report. Ann Palliat Med. 10:4999–5009. 2021. View Article : Google Scholar : PubMed/NCBI |
